UBS Group Cuts Elanco Animal Health (NYSE:ELAN) Price Target to $17.00

Elanco Animal Health (NYSE:ELAN) had its price target decreased by UBS Group from $18.00 to $17.00 in a research report report published on Wednesday,Benzinga reports. UBS Group currently has a buy rating on the stock.

A number of other research analysts have also recently weighed in on the stock. Stifel Nicolaus lowered their target price on shares of Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Friday, February 21st. Leerink Partners assumed coverage on Elanco Animal Health in a research report on Monday, December 2nd. They issued a “market perform” rating and a $14.00 price objective on the stock. Barclays dropped their price objective on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday. Leerink Partnrs raised Elanco Animal Health to a “hold” rating in a research note on Monday, December 2nd. Finally, Morgan Stanley dropped their price target on Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a research note on Wednesday. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, Elanco Animal Health currently has a consensus rating of “Hold” and a consensus target price of $15.57.

Elanco Animal Health Stock Performance

Shares of ELAN opened at $11.15 on Wednesday. The business has a 50-day simple moving average of $11.74 and a two-hundred day simple moving average of $13.06. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. Elanco Animal Health has a 52 week low of $10.20 and a 52 week high of $18.80. The stock has a market cap of $5.51 billion, a price-to-earnings ratio of 27.88, a PEG ratio of 2.50 and a beta of 1.42.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.01 billion. During the same period in the prior year, the company posted $0.08 earnings per share. The company’s revenue was down 1.4% compared to the same quarter last year. On average, analysts expect that Elanco Animal Health will post 0.91 EPS for the current year.

Institutional Trading of Elanco Animal Health

Several hedge funds have recently made changes to their positions in the business. AM Squared Ltd purchased a new position in Elanco Animal Health in the third quarter worth about $34,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Elanco Animal Health in the 3rd quarter valued at approximately $35,000. CoreCap Advisors LLC purchased a new position in shares of Elanco Animal Health in the 4th quarter worth approximately $29,000. Farther Finance Advisors LLC increased its position in shares of Elanco Animal Health by 158.7% during the 3rd quarter. Farther Finance Advisors LLC now owns 3,332 shares of the company’s stock valued at $49,000 after purchasing an additional 2,044 shares during the last quarter. Finally, Venturi Wealth Management LLC raised its holdings in Elanco Animal Health by 89.9% during the 3rd quarter. Venturi Wealth Management LLC now owns 3,382 shares of the company’s stock valued at $50,000 after buying an additional 1,601 shares during the period. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.